Introducing retatrutide Retatrutide is a new medication that targets the glucose-dependent insulinotropic polypeptide (GIP receptor), glucagon-like peptide-1 (GLP-1), and glucagon receptors (GCG receptors)
A molecule that fits perfectly into GLP-1 receptors might not activate GIP receptors effectively, and vice versa
In patients with an eGFR 30, no significant comorbidities, no relevant medical history, good health literacy, comfort with self-injection, and primary care follow-up elsewhere, the cost savings of compounded semaglutide may be acceptable if the patient understands they are using a non-FDA-approved product from a pharmacy whose quality they cannot independently verify
However, Retatrutide is currently unavailable for prescription, as it has not been submitted for FDA approval yet
Peptides similaires Versus tirzepatide (double agoniste GLP-1/GIP) : le retatrutide surpasse le tirzepatide en efficacite ponderale documentee
Causes drowsiness (useful at night, problematic during day)
